Surufatinib increases cholangiocarcinoma cells radiosensitivity by anti-tumor proliferation and inhibition of macrophage M2 polarization

This study confirmed the radiosensitizing effects of surufatinib on cholangiocarcinoma. The mechanism is that surufatinib can activate TLR3, up-regulate the expression of TRIF protein, increase DNA damage and apoptosis after radiation, and up-regulate NF- κB signal pathway to inhibit M2 polarization of tumor-associated macrophages, thus enhance radiosensitivity. In order to investigate the mechanism of surufatinib in enhancing radiotherapy sensitivity of cholangiocarcinoma, we used a cholangiocarcinoma cell line TFK1, and set up a blank control group, a radiotherapy group (6Gy), a chemotherapy group (surufatinib 4.33ng/ml), and a combination treatment group (surufatinib 4.33ng/ml+RT 6Gy). After 24 hours of treatment, total RNA was extracted for transcriptome sequencing in different treatment groups.